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ABSTRACT  
Objective: To evaluate the impact of highly-active antiretroviral therapy (HAART) on 
CMV transmission and breast milk level in the context of maternal HIV. 
Design: Specimens from a randomized trial conducted in Nairobi, Kenya between 2003-
2005 were used to compare CMV transmission and breast milk levels between mother-
infant pairs randomized to HAART versus short-course antenatal zidovudine plus single-
dose nevirapine (ZDV/sdNVP) for prevention of mother-to-child HIV transmission 
(PMTCT). 
Methods: Fifty-one antiretroviral-naïve women <32 weeks gestation, and CD4 between 
200-500 cells/mm3 were randomized at 34 weeks to begin either antenatal ZDV/sdNVP, 
or HAART through 6 months postpartum. Mean breast milk CMV levels and 
transmission were compared between arms. 
Results: Age, sociodemographics, CD4%, and HIV plasma RNA viral load were similar 
between arms at baseline. CMV viral loads were measured from 243 infant plasma and 
185 breast milk specimens during the first year postpartum. The probability of infant 
CMV infection at 12 months was 19% lower in the HAART arm compared to 
ZDV/sdNVP (75% vs. 94%, p=0.04). All women had CMV detected in breast milk, with 
72%, 98%, and 97% testing positive during the first, second and third weeks postpartum, 
respectively. There was a trend for early higher mean breast milk CMV level in the 
HAART arm at 1 week (p=0.08), and there was significantly slower decline in breast 
milk CMV levels (AUC, p=0.01). 
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Conclusions: HAART started during the third trimester may decrease infant CMV 
infections, by mechanisms independent of breast milk CMV levels. 
Clinical trials registration: NCT00167674  
Keywords: cytomegalovirus, human immunodeficiency virus, neonates, breast milk, 
antiretroviral therapy, HAART 
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INTRODUCTION 
Cytomegalovirus (CMV) is an important opportunistic infection in the setting of HIV, 
and is additionally associated with non-AIDS defining morbidity and mortality even in 
the absence of CMV disease1-5. In HIV-infected infants, CMV co-infection is associated 
with an increased risk of death, disease progression, and neurologic disease6-10. The 
importance of CMV on long-term outcomes in HIV-exposed uninfected infants is not yet 
clear. In Kenya most HIV-exposed children acquire CMV in the first year of life, 
regardless of HIV status9, with breast milk a major route of transmission11. CMV DNA is 
found in the breast milk of nearly all HIV-infected women, and breast milk CMV DNA 
level is associated with the risk of infant infection12. During pregnancy, CMV 
reactivation is also common in the cervix and is associated with the risk of intrapartum 
CMV transmission13-18.  
Maternal immunosuppression is associated with an increased risk of infant CMV 
infection9, and with higher CMV levels in the breast milk, cervix, and saliva12, 19 
suggesting maternal immune reconstitution during highly active antiretroviral therapy 
(HAART) may decrease vertical CMV transmission. Current data on the impact of 
HAART on vertical CMV transmission are conflicting. A retrospective analysis from the 
French Perinatal Cohort Study found a decline in the rate of congenital CMV infection 
with increased use of HAART over time, and less congenital CMV if maternal ART was 
started in the first or second trimester20. Another study reported a higher rate of 
congenital CMV among women who did not receive antiretrovirals in pregnancy versus 
those who did21. However, an observational study in South Africa found no difference in 
the rate of congenital CMV infection between women taking antenatal zidovudine versus 
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HAART for the prevention of mother-to-child HIV transmission (PMTCT)19.  The BAN 
study in Malawi initiated PMTCT in the delivery/postpartum period and did not observe 
a difference in CMV transmission between study arms22. Similarly, an observational 
study in Malawi found no decrease in breast milk CMV levels with maternal HAART in 
pregnancy compared to maternal single-dose nevirapine at labor23. 
In order to simplify the PMTCT cascade, and to maximize efficacy for preventing infant 
HIV transmission, many countries in sub-Saharan Africa are implementing WHO Option 
B (HAART for all pregnant women until 1 week after cessation of breastfeeding) or 
Option B+ (lifelong combination ART for all pregnant women)24. As more women access 
Option B/B+ PMTCT regimens, rates of vertical CMV transmission could decline. We 
hypothesized that maternal HAART would reduce the risk of infant CMV infection and 
breast milk CMV DNA levels. To test this hypothesis, we compared CMV transmission 
rates and breast milk CMV DNA levels among women receiving HAART to those 
receiving short-course antenatal zidovudine plus a single-dose of nevirapine at delivery 
(ZDV/sdNVP).  
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 METHODS 
Study design. This study utilized specimens and data from a phase II randomized trial 
comparing the effect of two different PMTCT regimens on breast milk HIV levels 
(NCT0016767425). The study had 80% power to detect a 0.81-log10 difference in breast 
milk CMV levels between arms; and 80% power to detect a hazard ratio (HR) of 0.65 or 
less.  
Subject selection, randomization. These studies were approved by the University of 
Washington Institutional Review Board and the Kenyatta National Hospital Ethics and 
Research Committee. Pregnant women were recruited and enrolled from the Mathare 
North Nairobi City Council Clinic from 2003-2005, as previously detailed in25. Eligibility 
criteria for the original study included intention to breastfeed, <32 weeks gestation, 
hemoglobin >8g/dl, no previous ART exposure, >18 years of age, agreeable to home 
visits, residence in catchment area, and CD4 >200 and <500 cells/mm3. Additional 
criteria for the CMV sub-study included completion of randomization procedures, receipt 
of intervention, and delivery of a live infant. At enrolment, women provided detailed 
information regarding sociodemographics, medical and obstetric history, and underwent a 
physical examination.  
At 34 weeks gestation, subjects were allocated to the HAART or ZDV/sdNVP arms using 
computer-generated block randomization. Women in the HAART arm received 300 mg 
zidovudine, 150 mg lamivudine, and 200 mg nevirapine twice-daily from 34 weeks until 
6 months postpartum. Women in the ZDV/sdNVP arm received 300 mg zidovudine 
twice-daily from 34 weeks until labor, then every 3 hours from labor until delivery plus 
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200 mg of nevirapine at the onset of labor plus a single 2 mg/kg (6 mg if birth weight > 
2.5 kg) oral dose of NVP suspension to the infant within 72 hours of delivery25. 
Specimen collection and follow-up. Blood was drawn for HIV plasma viral load and 
CD4 measurements at randomization, and women were seen weekly in clinic thereafter 
until their delivery. Within 48 hours of delivery, maternal blood was drawn for CD4 
count and HIV RNA levels and infant blood was drawn for HIV testing. Study staff 
conducted 1-3 home visits per week during the first month postpartum to collect breast 
milk, up to a total of 10 times; staff observed manual expression of 5-40 ml of milk from 
a single breast at each visit. Following removal of the lipid layer, breast milk supernatants 
were frozen at -80 ºC. Mothers and infants were followed up in clinic at 2 weeks and 1 
month, then every 3 months thereafter until 12 months postpartum. In addition to breast 
milk, mother and infant blood were collected at each clinic visit. 
Laboratory procedures. HIV RNA was measured as previously described25, 26 using the 
GenProbe assay27 (Gen-Probe Incorporated, San Diego, California); limits of detection 
were 100 copies/ml in breast milk and 200 copies/ml in plasma. Infant HIV was 
diagnosed from dried blood spots as previously described28. CD4 counts were performed 
using the Tri-test flow cytometry platform (Becton Dickinson, Franklin Lakes, New 
Jersey).  
CMV DNA was measured from breast milk supernatants and infant plasma using real-
time quantitative PCR detecting the glycoprotein B gene as previously described9. The 
limit of detection was 100 copies/ml for both breast milk and plasma. 
Statistical analyses. StataSE version 11.2 (College Station, Texas) was used for all 
analyses. All tests were two tailed with alpha=0.05. All comparisons between study arms 
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were conducted as intent-to-treat, unless stated otherwise. HIV and CMV viral load 
measurements below the limit of detection were recoded to the midpoint between zero 
and the limit of detection for each assay.  
The Mann-Whitney U test was used to make non-parametric comparisons between 
variables and Chi square or Fisher’s exact tests were used to compare proportions. CMV 
DNA loads in breast milk were compared between arms using the independent T test.  
Time to infant CMV acquisition and probabilities of CMV infection were estimated using 
Kaplan-Meier survival analysis; survival functions were compared using the log-rank 
test. The first detection of CMV DNA was estimated as the time of infant CMV 
acquisition; infants were considered at risk from birth and data were censored at study 
exit or death, whichever came first. The z-test was used to compare the probability of 
infant CMV infection at 3, 6 and 12 months of age. Week 1 and week 2 breast milk CMV 
viral loads were defined as the last measurement for each woman collected during the 
first 8 days (N=45) and first 15 days postpartum (N=46), respectively. 
For comparison of breast milk CMV decline over time, area under the curve (AUC) was 
estimated for each individual woman, and then mean AUC was calculated across 
randomization arms, and compared using an independent T test. Visits were limited to 
<=100 days postpartum for this analysis since women in the HAART arm had more 
follow-up visits after this time, which would artificially inflate their AUC.  
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RESULTS 
Cohort characteristics. Patient selection and follow-up are shown in Figure 1. From a 
total of 58 women randomized in the parent trial, 51 met criteria for the CMV sub-study, 
26 were allocated to HAART and 25 were allocated to ZDV/sdNVP. All mother-infant 
pairs underwent CMV assays in the HAART arm. In the ZDV/sdNVP arm, 1 infant died 
before blood could be collected, and 2 women had inadequate breast milk volumes 
remaining for CMV testing.  
There were no significant differences in demographics, obstetric history, baseline HIV 
plasma viral load or CD4 count between women in the two study arms (Table 1). The 
duration of follow-up and breastfeeding were also similar between women in the two 
arms. However, women randomized to HAART (median=4 visits, IQR=3-5) had more 
breast milk samples tested for CMV compared to the ZDV/sdNVP arm (median=3 visits, 
IQR=3-4; p=0.01) because they tended to breastfeed longer. Three infants acquired HIV 
during the study; one in ZDV/sdNVP arm and two in the HAART arm. In contrast to the 
ZDV/sdNVP arm, in which the last antiretroviral dose was given at delivery, women in 
the HAART arm continued their antiretrovirals for a median of 205 days overall 
(IQR=162-225), and 171 days postpartum (IQR=145-182). No women in the HAART 
arm stopped ART before the first month postpartum. 
CMV transmission by randomization arm. A total of 243 CMV viral loads were 
measured from infant plasma specimens. Among the 50 infants evaluated, 42 acquired 
CMV (84%) by 1 year of age. Two CMV infections were detected at birth (4.0%), and 
both were in the HAART arm. Figure 2 shows Kaplan-Meier survival curves for CMV 
DNA detection in the two groups in the intent-to-treat analysis. The curves are similar 
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until 3 months of age, at which time they diverge. The probability of infant CMV 
infection was significantly lower in the HAART arm compared to the ZDV/sdNVP arm 
at 6 and 12 months of age (Table 2, p=0.04 and p=0.04, respectively); with a 1-year 
probability of CMV infection of 0.75 in the HAART arm and 0.94 in the ZDV/sdNVP 
arm (Table 2). The median time to CMV infection was 3.0 months (95%CI=3.0-3.2) in 
the ZDV/sdNVP arm, and 3.1 months (95% CI=2.9-6.1) in the HAART arm (p=0.2). 
HAART was associated with a hazard ratio (HR) of 0.69 in unadjusted analyses 
(95%CI=0.37-1.3; p=0.2), and an HR of 0.52 (95%CI=0.26-1.0; p=0.06) and 0.57 
(95%CI=0.30-1.1; p=0.09) when adjusting for week 1 and week 2 maternal CMV breast 
milk levels, respectively. Neither breast milk CMV levels (week 1 or week 2), baseline 
maternal plasma HIV viral load, or baseline maternal CD4 percent were not associated 
with CMV transmission (data not shown). 
Results were similar when excluding the 3 infants who acquired HIV infection (data not 
shown), and when analyzing the data “as-treated,” where women were censored when if 
they stopped taking HAART early (data not shown).  
Breast milk CMV detection and levels. A total of 185 CMV DNA measurements were 
conducted in breast milk from 49 women. CMV DNA was detected at least once in the 
breast milk of all women studied. Breast milk CMV was detected as early as 1 day 
postpartum (3/4 women screened in the first day postpartum), and was detected in 72% of 
women providing specimens during the first week of life. By 2 weeks postpartum, 98% 
of women had detectable CMV DNA in breast milk.   
During the first week postpartum, there was a trend for more frequent detection of CMV 
DNA (p=0.06) and higher CMV DNA levels (p=0.08) in the breast milk of women 
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randomized to HAART compared to ZDV/sdNVP (Table 3). CMV viral loads peaked at 
approximately 3-4 weeks and slowly declined thereafter in both groups (data not shown). 
Peak breast milk CMV loads were similar between the two arms (ZDV/sdNVP mean=5.2 
+SD=1.1 log10 CMV DNA copies/ml, versus HAART mean=5.4 log10 CMV DNA 
copies/ml, +SD=0.94; p=0.5). CMV loads in the HAART arm declined more slowly than 
in the ZDV/sdNVP arm, as reflected by higher mean AUC (p=0.01).  
DISCUSSION  
As more women begin taking HAART before or during pregnancy, there is the potential 
for a secondary impact on vertical CMV transmission. In this small randomized trial, 
maternal HAART was associated with a lower risk of infant CMV infection at 6 and 12 
months of age, but was not associated with lower maternal breast milk CMV levels. In 
contrast to our hypothesis, there was a trend for modestly increased breast milk CMV 
levels in women receiving HAART. Together these data suggest that maternal HIV 
treatment lowers the risk of CMV infection, but this effect is not mediated by reduction 
of breast milk CMV replication.  
There was a lower risk of CMV infection in the HAART arm at 6 and 12 months. This 
observation is consistent with reports from observational studies reporting lower rates of 
CMV transmission in cohorts following the introduction of HAART20, and our own 
observation of later CMV transmission in successive cohorts studied over secular time, 
who were exposed to increasingly efficacious PMTCT regimens9, 11, 29. Our study is also 
consistent with a study in Malawi that found no difference between breast milk CMV 
DNA levels at 4-6 weeks postpartum in HAART-treated women compared to women 
receiving single-dose NVP23.  
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Our data suggest the risk of transmission was modified through mechanisms distinct from 
reducing breast milk CMV levels. The striking increase in CMV infections at 3 months 
likely reflects increasing vulnerability of children to CMV acquisition with waning 
maternal antibodies as well as acquisition of breast milk-derived virus. Equivalence of 
the survival curves before 3 months of age suggests HAART started late in pregnancy did 
not likely impact in utero or intrapartum CMV transmission in our study. It will be 
important to determine the association between HAART duration and CMV kinetics to 
understand the population impact on CMV transmission as Option B+ rolls out across 
sub-Saharan Africa. 
CMV DNA was detected at high levels in the breast milk of most women sampled during 
the first week postpartum, and peaked at approximately 1 month postpartum, following a 
pattern similar to that observed in HIV-uninfected women30, 31. Contrary to our 
hypothesis, women randomized to HAART for PMTCT had a trend for higher CMV 
DNA levels in the breast milk during the early postpartum period, and had a significantly 
slower decline in CMV levels. Fortunately this paradoxical increase did not result in 
greater CMV transmission risk for women on HAART. Higher CMV loads in the 
HAART arm were unexpected, but may be explained by changes in the inflammatory 
environment following HAART initiation. Gianella and colleagues reported a paradoxical 
increase in vaginal CMV shedding in non-pregnant Ugandan women starting ART32; the 
women started ART according to immunologic/clinical criteria and the authors 
hypothesized that CMV reactivation could be due to inflammation induced by immune 
reconstitution, which could be conducive to localized CMV replication. Reactivation 
secondary to ART initiation has also been observed for HSV-2 in the vagina33. It is 
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possible that localized inflammation secondary to immune reconstitution in the breast 
tissue or the milk could explain the increased CMV replication observed in our study. If 
this is the case, earlier initiation of HAART (prior to conception or during early 
pregnancy) may provide more time for inflammation to decline before lactation.  
Our study has several important strengths, including longitudinal assessment of early 
breast milk viral levels and infant CMV. Limitations include the narrow range of 
maternal CD4 counts and late initiation of HAART, which may have attenuated our 
ability to detect differences between study arms.   
In summary, although our study was small, our data suggests HAART reduces the risk of 
CMV transmission from HIV-infected women. As WHO Option B+ becomes available to 
an increasing number of women in sub-Saharan Africa, it will be important to determine 
the impact of longer-term maternal HAART on CMV transmission and maternal CMV 
replication. 
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Table 1: Cohort characteristics of mother-infant pairs with CMV testing.  
 
 Median (IQR) or % (n/N)  
 ZDV/sdNVP 
(n=25) 
HAART 
(n=26) 
p 
Enrollment    
Maternal age 24 (20-30) 26 (24-29) 0.5 
Years education 8 (8-10) 8 (7-12) 0.3 
People in home 3 (2-4) 3 (2-4) 0.6 
Gravidity 1 (0-2) 2 (1-2) 0.5 
Living children 1 (0-2) 1 (1-2) 0.6 
Parity 1 (0-2) 1 (1-2) 0.5 
Primiparous 32% (8/25) 19% (5/26) 0.3 
Maternal plasma HIV-1 RNA copies/ml 4.8 (4.2-5.3) 4.8 (4.4-5.0) 1.0 
Maternal CD4 cells/mm3 360 (295-423) 283 (248-426) 0.3 
    
Follow-up and testing    
Months of follow-up postpartum 12 (9.0-12) 12 (9.1-12) 1.0 
Duration of breast feeding 5.2 (3.0-6.0) 6.0 (5.1-6.1)a 0.2 
Duration of PMTCT since 
randomization 
1.4 (1.0-1.6) 6.7 (5.3-7.4) <0.001 
Duration of postpartum HAART  NA 5.6 (4.8-6.0) NA 
Number of study visits 5 (4-6) 6 (5-6) 0.08 
 21 
Breast milk samples tested for CMV 3 (3-4)b 4 (3-5) 0.01 
Infant samples tested for CMV 5 (3.5-6)c 6 (4-6) 0.1 
Infant HIV-1 infections 4.0% (1/25) 8.0% (2/26) 1.0 
Notes. NA, not applicable. an=25, bn=23, cn=24. 
 
  
 22 
Table 2. Probability of infant CMV infection by PMTCT regimen. 
 Mean probability of CMV infection [95%CI] 
 Month 3 Month 6 Month 12 
ZDV/sdNVPa 0.46 [0.29, 0.67] 0.83 [0.66, 0.95] 0.94 [0.77, 0.99] 
HAART 0.38 [0.23, 0.60] 0.62 [0.43, 0.80] 0.75 [0.57, 0.90] 
P value 0.3 0.04 0.04 
Notes. aInfants also received a single dose of NVP at birth in this treatment group. 
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Table 3. Breast milk CMV replication in the first 4 weeks postpartum. 
 
 CMV detection 
% (n/N) 
 Log10 CMV DNA levelb 
Mean (+SD) 
 Week 1 
(day 1-8) 
Week 2 
(day 9-19) 
Week 3-4 
(day 20-37) 
  Week 1 
(day 1-8) 
Week 2 
(day 9-19) 
Week 3-4 
(day 20-37) 
Overall 72% (34/47) 98% (39/40) 97% (35/36)  3.3 (+1.2) 4.8 (+1.1) 5.1 (+1.3) 
ZDV/sdNVP 59% (13/22) 95% (20/21) 100% (17/17)  3.0 (+1.2) 4.6 (+1.1) 5.0 (+1.4) 
HAART 84% (21/25) 100% (19/19) 94% (18/19)  3.6 (+1.1) 5.1 (+0.93) 5.2 (+1.2) 
P value  0.06a 1.0a 1.0a  0.08b 0.1b 0.7b 
Notes. Each woman is represented once per time interval, using the value collected closest to the midpoint of the 
interval. P values for comparison of ZDV/sdNVP and HAART arms. aFisher’s exact test. bT test. 
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FIGURE LEGENDS 
Figure 1. Subject selection and randomization. 
Figure 2. CMV DNA levels and transmission. Kaplan-Meier survival functions show 
the probability of infant CMV infection by PMTCT treatment in randomized infants (47 
HIV-exposed uninfected and 3 HIV-infected). P value for log-rank test. 
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- Received allocated intervention (n=25)
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